Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
- PMID: 12730697
- DOI: 10.1038/ng1161
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
Comment in
-
One-shot, one cure with genome editing for dyslipidemia.Circ Cardiovasc Genet. 2014 Dec;7(6):967-8. doi: 10.1161/CIRCGENETICS.114.000958. Circ Cardiovasc Genet. 2014. PMID: 25516627 No abstract available.
Similar articles
-
Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.Hum Mutat. 2005 Nov;26(5):497. doi: 10.1002/humu.9383. Hum Mutat. 2005. PMID: 16211558
-
Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.Atherosclerosis. 2012 May;222(1):158-66. doi: 10.1016/j.atherosclerosis.2012.02.018. Epub 2012 Feb 19. Atherosclerosis. 2012. PMID: 22417841
-
Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.Curr Opin Lipidol. 2005 Apr;16(2):167-72. doi: 10.1097/01.mol.0000162321.31925.a3. Curr Opin Lipidol. 2005. PMID: 15767856 Review.
-
Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1448-53. doi: 10.1161/01.ATV.0000133684.77013.88. Epub 2004 May 27. Arterioscler Thromb Vasc Biol. 2004. PMID: 15166014
-
Genetic heterogeneity of autosomal dominant hypercholesterolemia.Clin Genet. 2008 Jan;73(1):1-13. doi: 10.1111/j.1399-0004.2007.00915.x. Epub 2007 Nov 16. Clin Genet. 2008. PMID: 18028451 Review.
Cited by
-
Genetics of coronary artery disease and myocardial infarction--2013.Curr Cardiol Rep. 2013 Jun;15(6):368. doi: 10.1007/s11886-013-0368-0. Curr Cardiol Rep. 2013. PMID: 23616109 Review.
-
Pathway and network-based strategies to translate genetic discoveries into effective therapies.Hum Mol Genet. 2016 Oct 1;25(R2):R94-R98. doi: 10.1093/hmg/ddw160. Epub 2016 Jun 23. Hum Mol Genet. 2016. PMID: 27340225 Free PMC article. Review.
-
The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.J Biol Chem. 2012 Dec 21;287(52):43492-501. doi: 10.1074/jbc.M112.394023. Epub 2012 Oct 26. J Biol Chem. 2012. PMID: 23105118 Free PMC article.
-
Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids.J Clin Lipidol. 2013 May-Jun;7(3 Suppl):S1-5. doi: 10.1016/j.jacl.2013.03.005. Epub 2013 Mar 26. J Clin Lipidol. 2013. PMID: 23642322 Free PMC article.
-
PCSK9 Monoclonal Antibodies Have Come a Long Way.Curr Atheroscler Rep. 2024 Dec;26(12):721-732. doi: 10.1007/s11883-024-01243-1. Epub 2024 Oct 10. Curr Atheroscler Rep. 2024. PMID: 39384735 Review.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
